Search | Clinical Trials Finder

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions: nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX), Theratears tear drop, (Akron, Ann 111 Arbor, MI), patching; Drug · Other
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Major
Interventions: Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support; Drug · Behavioral
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more

Conditions: Alcoholism
Interventions: Acamprosate, Naltrexone, Placebo; Drug
Lead sponsor: The Scripps Research Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Osteoporosis, Post-menopausal
Interventions: Romosozumab, Alendronate (Fosamax), Placebo Romosozumab, Placebo Alendronate; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Blood Pressure
Interventions: MENT or placebo; Drug
Lead sponsor: Population Council; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Dengue
Interventions: ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo; Drug · Other
Lead sponsor: Island Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: East Syracuse, New York

Conditions: Athletic Performance
Interventions: Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement, Broad Spectrum Safety; Dietary Supplement
Lead sponsor: Victory Nutrition International, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cornelius, North Carolina

Conditions: Opioid Use Disorder
Interventions: AZD4041, Itraconazole, Buprenorphine, Buprenorphine / Naloxone, Hydromorphone, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Major Depressive Disorder
Interventions: amibegron (SR58611A); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Experimental: CHF6001 1600µg, Experimental: CHF6001 3200µg, Placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 40 Years and older
Enrollment: 4,710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 15
States / cities: Sheffield, Alabama • Northridge, California • Cutler Bay, Florida + 9 more

Conditions: Achondroplasia
Interventions: BMN 111, Normal Saline; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 22 Years to 45 Years · Male only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Osteoporosis
Interventions: Teriparatide, Risedronate, Placebo, Calcium, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 6
States / cities: Fort Lauderdale, Florida • New Port Richey, Florida • Orlando, Florida + 3 more

Conditions: Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis
Interventions: Delamanid, Optimized Background Regimen (OBR), Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hypoglycemia
Interventions: Eplerenone, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 40 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cirrhosis, Liver, Advanced Liver Fibrosis
Interventions: erlotinib hydrochloride, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Alzheimer's Disease, Dementia
Interventions: Drug: EVP-6124, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 44
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 41 more

Conditions: Malaria
Interventions: Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp), Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp), Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lassa Fever
Interventions: LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU; Biological · Other
Lead sponsor: Wilbur Chen, MD, MS; Other
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypovitaminosis D
Interventions: 25 Hydroxy- Vitamin D3 [25 (OH) D3], Placebo; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 70 Years
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Tardive Dyskinesia
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 48
States / cities: Little Rock, Arkansas • Anaheim, California • Glendale, California + 45 more

Conditions: Bioavailability and Pharmacokinetics
Interventions: LBR-101 IV, LBR-101 SC; Biological
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Post-operative Pain
Interventions: Ibuprofen/acetaminophen, Ibuprofen/acetaminophen (higher dose), Nurofen Plus®, Panadeine® Extra, Placebo; Drug
Lead sponsor: Reckitt Benckiser LLC; Industry
Eligibility: 16 Years and older
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Subjects
Interventions: Placebo comparator, Single Active dose, Double Active dose; Other
Lead sponsor: Dairy A Day, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Healthy Volunteers
Interventions: PRT064445/Apixaban, Placebo/Apixaban, Placebo; Combination Product · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

Post Intravitreal Injection Topical NSAID vs. Patching

Psilocybin for Major Depressive Disorder (MDD)

Medication Development in Alcoholism: Acamprosate Versus Naltrexone

Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes

A Two-part Trial Assessing the Effects of 7α-methyl-19-nortestosterone (MENT) on Blood Pressure in Normal Men: an Open-label Pilot Study Followed by a Randomized, Double-blind, Placebo-controlled Study

Study to Examine the Effects of Oral Fenretinide

Clinical Study on Prodovite® VMP35 Supplement on Athletic Performance

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)

Hypoglycemia and the Mineralocorticoid Receptor

Erlotinib for Hepatocellular Carcinoma Chemoprevention

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model

DMID 23-0015; Lassa Fever CVD 1000

To Study the Nutri-Genomic Response of Vit-D Supplementation in African-Americans

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Safety and Bioavailability of IV and SC LBR-101

Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study

"Fermented Dairy Beverage on Inflammation/Immune Function in Stressful Exercise"

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)